

S2 Doc: Eligibility criteria for selection of studies

Criteria:	
1	<p>“examines the impact of a prognostic marker on a clinical outcome”</p> <p>focus on prognostic value of a marker on an outcome of clinical importance in humans</p>
2	<p>“outcome is overall and/or disease-free survival”</p> <p>considered outcome is time between diagnosis, study entry or similar and an event such as death, disease-related death, progression, recurrence analysis based on survival techniques (Kaplan-Meier, log-rank, Cox/proportional hazard, ...)</p>
3	<p>“study analysis is NOT DNA microarray, gene profiling or proteomic study i.e we EXCLUDE DNA microarray”</p> <p>excluding any marker study that is related to the analysis of high-dimensional data (discovery study)</p>
4	<p>“single marker is focus of paper”</p> <p>focus on analysis of prognostic value of single markers excluding studies that try to develop signatures or scores</p>
5	<p>“biological marker”</p> <p>Including: any lab measurement, immunohistochemistry, DNA/RNA measurements, already developed scores (e.g. staging scores) Excluding: weight (kg), BMI, angiogenesis (ultrasound), any clinical tests such as of reflexes, lymph drainage pattern (Scan), ethnical origin</p>
6	<p>“two or more variables included in the model”</p> <p>besides biomarker other variable(s) such as known prognostic factors (e.g. age) should be considered in multivariate analysis</p>
7	
8	<p>„cancer“</p> <p>any form of cancer in humans, except in-situ cancer</p>